Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Trading Statement

17 Aug 2006 07:44

Stanelco PLC17 August 2006 Stanelco PLC17 August 2006 Stanelco PLC ("Stanelco" or "the Company") 17 August 2006 Trading update The Company announced on the 14th July 2006 in its interim results for the sixmonth period ending 30 April 2006 that its closing cash position at 30 April2006 was GBP0.3m. The Company started the period with a cash balance of GBP4.4mand made investments in research and development of GBP0.6m and increased itslevels of stock from GBP2.6m at the year end to GBP3.1m. The Company alsoinvested GBP1.2m in capital expenditure in the period. Since the half year end, the Company raised GBP3.7m (net of expenses) by way ofan equity placing in June 2006 of which GBP1.6m was used to meet a stage paymentfor the acquisition of Biotec and GBP2.1m was for working capital purposes. Ofthat GBP2.1m, GBP2.0m has been used for the ongoing commercialisation of theGroup's technologies and meeting the Group's operational running expenses since1 May 2006, and GBP0.1m has been used for capital expenditure. The Company also stated in those interim results that it was considering itsfunding requirements and funding options for the next phase of its development.As at today's date the Company has cash at bank of GBP0.9m with an unusedoverdraft facility of GBP0.2m. The Company estimates that its current cash at bank of GBP0.9m, together withprojected receivables and working capital needs is sufficient to meet its cashrequirements for a further three months in the absence of further funding or newrevenue streams commencing in the period. Since 2000, Stanelco's business model has transformed from a manufacturer andsupplier of capital goods into an intellectual property company with interestsin markets with significant growth potential, which include sustainablepackaging and environmentally responsible sealing solutions for the packagingindustry. As indicated in the interim results, in order to enable the Group to move intothe next phase of the commercialisation of its intellectual property portfolioand to meet its working capital requirements, the Company is currently exploringall financing options including a public equity issue. The Company will update the market once any further information is available. Martin Wagner, Stanelco Chief Executive said: "While the Company is exploring all of its financing options, it continues toactively progress the commercialisation of its products. The Company is in advanced negotiations with a number of potential joint venturepartners in the USA to compound biodegradable resin. This is to meet thedemands currently expressed to Stanelco by major multiple retailers and globalfast food chains. Letters of intent with two of these companies have beenexchanged and the Company believes that these will lead to contracts in theshort term. We acknowledge that Stanelco has encountered delays in rolling out GREENSEAL tothe market. The delays have primarily resulted from the limitations of the foodpackaging industry to allow access to machines to test the technology in afactory environment. The Board believes that these delays will not impact onthe potential success of the project." Contact Martin WagnerChief Executive02380 867 100 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
3rd Sep 20127:00 amRNSInterim Results
29th Aug 20127:00 amRNSPrototype Delivery for Stanelco RF Technologies
19th Jul 20127:00 amRNSInterim Trading Statement
17th Jul 20127:00 amRNSFinancing and Loan Repayment
12th Jul 20127:00 amRNSPatent Litigation Update
10th Jul 20124:40 pmRNSSecond Price Monitoring Extn
10th Jul 20124:35 pmRNSPrice Monitoring Extension
19th Jun 20127:00 amRNSLoan Facility Extension/Directorate Change
31st May 20127:00 amRNSTrading Update
15th May 20124:40 pmRNSSecond Price Monitoring Extn
15th May 20124:35 pmRNSPrice Monitoring Extension
25th Apr 20121:35 pmRNSResult of AGM
25th Apr 20127:00 amRNSTrading Update
4th Apr 20127:00 amRNSNotification of Award under the Public Equity Plan
29th Mar 20127:00 amRNSPreliminary Results
19th Jan 20127:00 amRNSPre-close Trading Statement
10th Jan 20127:00 amRNSContract for RF Technologies Business
16th Dec 20111:27 pmRNSDirector/PDMR Shareholding
6th Dec 20117:00 amRNSLoan Reclassification
4th Nov 20117:00 amRNSTrading Update
21st Oct 20114:35 pmRNSPrice Monitoring Extension
19th Sep 20117:00 amRNSSector Reclassification
1st Sep 20117:01 amRNSDirectorate Changes
1st Sep 20117:00 amRNSInterim Results
16th May 201111:07 amRNSDirector/PDMR Shareholding
9th May 20117:00 amRNSDirector/PDMR Shareholding
5th May 20112:28 pmRNSResult of AGM
5th May 20117:00 amRNSTrading Update
12th Apr 201112:22 pmRNSHolding(s) in Company
28th Mar 20114:23 pmRNSAnnual Report &Accounts for 2010 and Notice of AGM
24th Mar 20117:00 amRNSPreliminary Results
28th Feb 201112:22 pmRNSTotal Voting Rights
23rd Feb 20114:40 pmRNSSecond Price Monitoring Extn
23rd Feb 20114:35 pmRNSPrice Monitoring Extension
17th Feb 20117:00 amRNSAppointment of Nominated Adviser & Joint Brokers
5th Nov 20107:00 amRNSTrading Update
14th Oct 20107:00 amRNSDirector/PDMR Shareholding
7th Oct 20107:00 amRNSDirectorate Change
5th Oct 20107:00 amRNSNotification of Awards under Public Equity Plan
17th Sep 20104:37 pmRNSPrice Monitoring Extension
27th Aug 20107:00 amRNSHalf Yearly Report
13th Jul 20107:55 amRNSFirst Day of Dealings on AIM
12th Jul 20107:00 amRNSChange of Name
1st Jul 201010:07 amRNSTotal Voting Rights
22nd Jun 20101:07 pmRNSResult of AGM
22nd Jun 20107:00 amRNSAnnual General Meeting & Trading Update
21st Jun 20104:41 pmRNSSch 1 update - Stanelco plc
21st Jun 20104:15 pmRNSDirector/PDMR Shareholding: Correction
15th Jun 20105:03 pmRNSDirector/PDMR Shareholding
14th Jun 201012:40 pmRNSSchedule 1 - Stanelco PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.